-
Mashup Score: 1
Distinct survival outcomes were found to correlate with VCK versus CK and the interplay between cytogenetic abnormalities and TP53 mutation status in patients with MDS
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2Early Study Looks at Combining HMA with Immunotherapy-Based Regimens in MDS | Blood Cancers Today - 2 day(s) ago
A phase 2 trial of immunotherapy-based HMA combinations for patients with previously untreated MDS showed that there are unique cytogenic and molecular predictors of response.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet-
A phase 2 trial led by Ian Bouligny, MD, of @MDAndersonNews, explored immunotherapy-based HMA combinations for patients with previously untreated #MDS. 📰 Read more: https://t.co/kuqk3YG3At https://t.co/mJ2WegmtOL
-
-
Mashup Score: 1Data Suggest Azacitidine, Nivolumab Is Best Immunotherapy Regimen for MDS | Blood Cancers Today - 5 day(s) ago
Azacitidine/nivolumab showed improved responses overall and superior OS between intermediate-risk subgroups when compared with azacitidine/ipilimumab in patients with MDS.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
Data suggest that azacitidine and nivolumab is the best immunotherapy regimen for #MDS. Read more from the study led by Ian Bouligny, MD, of @MDAndersonNews. ➡️ https://t.co/v9j4e8XlfQ https://t.co/uRBMsGpAQj
-
-
Mashup Score: 0“I Thought He Was Helping Me”: Patient Endured 9 Years of Chemotherapy for Cancer He Never Had - 6 day(s) ago
Oncologist Thomas C. Weiner misdiagnosed Anthony Olson with MDS in 2011. Olson is one of many patients who may have received unnecessary and harmful treatments after being misdiagnosed by Weiner.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Oncologist Thomas C. Weiner misdiagnosed Anthony Olson with #MDS in 2011. https://t.co/bCqw7I4Txy
-
-
Mashup Score: 1Combination Therapy With HMA and Venetoclax Improved Outcomes in Higher-Risk MDS | Blood Cancers Today - 7 day(s) ago
Adding venetoclax to hypomethylating agents significantly improved response rates in participants with higher-risk myelodysplastic syndrome in a retrospective analysis
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🎉 Combination therapy with HMA and venetoclax improved outcomes in higher-risk #MDS, according to a study presented by Mihir Shukla, MD, of @nyugrossman. 💡 Learn more: https://t.co/PHWai0PKEo https://t.co/sKbEgyj63V
-
-
Mashup Score: 4Sequencing Therapies in LR-MDS - 9 day(s) ago
Panelists discuss second-line (2L) treatment strategies for lower-risk myelodysplastic syndrome (LR-MDS), focusing on how to choose a 2L treatment for patients refractory to first-line options, and provide an overview of recent updates from the IMerge trial (Santini et al, EHA 2024; Zeidan et al, JCO 2024), while considering the role of imetelstat in treatment sequencing according to NCCN Guidelines MDS-5.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
In this video, @MdSwoboda and @garciamanero discuss second-line treatment strategies for lower-risk myelodysplastic syndrome. #MDS https://t.co/7eHvtnplcG
-
-
Mashup Score: 3Dose Escalation of Luspatercept Is Underutilized in MDS - 16 day(s) ago
Saeed Sadeghi, MD, discusses valuable feedback he heard from oncologists on the use of luspatercept-aamt in patients with low-risk myelodysplastic syndrome.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH NOW: Saeed Sadeghi, MD, (@SaeedokMD) discusses valuable feedback he heard from oncologists on the use of luspatercept-aamt in patients with low-risk myelodysplastic syndrome. #MDS https://t.co/hDcdt4Mvbz
-
-
Mashup Score: 4
During a Case-Based Roundtable® event, Andrew M. Brunner, MD, discussed dosing strategy for erythropoiesis-stimulating agents as well as dose modifications and safety for the novel agents imetelstat and luspatercept.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Andrew M. Brunner, MD, discussed dosing strategy for erythropoiesis-stimulating agents as well as dose modifications and safety for the novel agents imetelstat and luspatercept.#MDS https://t.co/AujIfbMPYk https://t.co/Su6BsWmZxc
-
-
Mashup Score: 2
Solly Chedid, MD, discussed luspatercept and its role in boosting quality of life for patients with myelodysplastic syndrome.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Solly Chedid, MD, discussed luspatercept and its role in boosting quality of life for patients with myelodysplastic syndrome. #MDS @mySingingRiver https://t.co/g1nsIVIV5U https://t.co/YKN5ppLyFY
-
-
Mashup Score: 1
Findings from the Myelodysplastic Syndromes Natural History Study support the clinical value of targeted interventions for patients at high risk of progression.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
📝 @AmyDeZern, of @HopkinsMedicine, and colleagues presented new insights into #MDS disease progression and risk stratification based on data from the MDS Natural History Study, a landmark project sponsored by the @NIH. 💡 Learn more: https://t.co/AuUEHYAgJW https://t.co/3x5sQGvfgm
-
Blood Cancers Today Spoke with Ted Getz, MD, of @YaleMed, on findings from the International Consortium for MDS VALIDATE database, which sheds light on the prognostic impact of cytogenetic risk for patients with #MDS treated with HMAs. 📚 Read here: https://t.co/dD16Oj1hOj https://t.co/5iVGf97uuu